Pyranonaphthoquinone lactones: A new class of AKT selective kinase inhibitors alkylate a regulatory loop cysteine

Journal of Medicinal Chemistry

Volumn 52, Issue 8, 2009, Pages 2181-2184

  Salaski, Edward J ^a   Krishnamurthy, Girija ^a   Ding, W D ^a   Yu, Ker ^a   Insaf, Shabana S ^a   Eid, Clark ^a   Shim, Jaechul ^a   Levin, Jeremy I ^a   Tabei, Keiko ^a   Toral Barza, Lourdes ^a   Zhang, W G ^a   Mcdonald, Leonard A ^a   Honores, Erick ^a   Hanna, Cilien ^a   Yamashita, Ayako ^a   Johnson, Bernard ^a   Li, Zhong ^a   Laakso, Leif ^a   Powell, Dennis ^a   Mansour, Tarek S ^a  

^a WYETH RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL MARKER; CYSTEINE; DEOXYFRENOLICIN; FRENOLICIN B; KALAFUNGIN; LACTONE DERIVATIVE; LACTOQUINOMYCIN; PROTEIN KINASE B INHIBITOR; PYRANONAPHTHOQUINONE LACTONE DERIVATIVE; UNCLASSIFIED DRUG;

ALKYLATION; ANTINEOPLASTIC ACTIVITY; ARTICLE; BIOREDUCTIVE ALKYLATION; CANCER CELL CULTURE; CELL ASSAY; DRUG MECHANISM; DRUG POTENCY; DRUG SELECTIVITY; DRUG SYNTHESIS; ENZYME ASSAY; ENZYME INHIBITION; HUMAN; HUMAN CELL; IC 50; MITOSIS INHIBITION; REDUCTION; STRUCTURE ACTIVITY RELATION;

ALKYLATION; ANTINEOPLASTIC AGENTS; BIOLOGICAL MARKERS; CELL LINE, TUMOR; CELL PROLIFERATION; CYSTEINE; HUMANS; LACTONES; NAPHTHOQUINONES; ONCOGENE PROTEIN V-AKT; PYRANS; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 65249178820     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm900075g     Document Type: Article

References (31)

1. Fayard, E.; Tintignac, L. A.; Baudry, A.; Hemmings, B. A. Protein kinase B/AKT at a glance. J. Cell Sci. 2005, 118, 5675-5678.
2. (a) Vivanco, I.; Sawyers, C. L. The phosphatidylinositol 3-kinase-AKT pathway in human cancer. Nat. Rev. Cancer 2002, 2, 489-501.
3. (b) Bellacosa, A.; Kumar, C. C.; DiCristofano, A.; Testa, J. R. Activation of AKT kinases in cancer: implications for therapeutic targeting. Adv. Cancer Res. 2005, 94, 29-86.
4. LoPiccolo, J.; Granville, C. A.; Gills, J. J.; Dennis, P. A. Targeting AKT in cancer therapy. Anti-Cancer Drugs 2007, 18, 861-874.
5. (a) Takano, S.; Hasuda, K.; Ito, A; Koide, Y.; Ishii, F.; Haneda, I.; Chihara, S.; Koyama, Y. A new antibiotic, medermycin. J. Antibiot. 1976, 29, 765-768.
6. (b) Tanaka, N.; Okabe, T.; Isono, F.; Kashiwagi, M.; Nomoto, K.; Takahashi, M.; Shimazu, A.; Nishimura, T. Lacto-quinomycin, a novel anticancer antibiotic. I. Taxonomy, isolation and biological activity. J. Antibiot. 1985, 38, 1327-1332.
7. (c) Okabe, T.; Nomoto, K.; Funabashi, H.; Okuda, S.; Suzuki, H.; Tanaka, N. Lactoquinomycin, a novel anticancer antibiotic. II. Physicochemical properties and structure assignment. J. Antibiot. 1985, 38, 1333-1336.
8. (a) Bergy, M. E. Kalafungin, a new broad spectrum antibiotic: Isolation and characterization. J. Antibiot. 1968, 21, 454-457.
9. (b) Hoeksema, H.; Krueger, W. C. Kalafungin. II. Chemical transformations and the absolute configuration. J. Antibiot. 1976, 29, 704-709.
10. Iwai, Y.; Kora, A.; Takahashi, Y.; Ayashi, T.; Awaya, J.; Masuma, R.; Oiwa, R.; Omura, S. Production of deoxyfrenolicin and a new antibiotic, frenolicin B by Streptomyces roseofulvus strain AM-3867. J. Antibiot. 1978, 31, 959-965.
11. Toral-Barza, L.; Zhang, W.-G.; Huang, X.; McDonald, L. A.; Salaski, E. J.; Barbieri, L. R.; Ding, W.-D.; Krishnamurthy, G.; Hu, Y.; Lucas, J.; Bernan, V. S.; Cai, P.; Levin, J. I.; Mansour, T. S.; Gibbons, J. J.; Abraham, R. T.; Yu, K. Discovery of lactoquinomycin and related pyranonaphthoquinones as potent and allosteric inhibitors of AKT /PKB: Mechanistic involvement of AKT catalytic activation loop cysteines. Mol. Cancer. Ther. 2007, 6, 3028-3038.
12. Amer, R. E.; Dutton, C. J.; Fenner, B. R.; Greenwood, S. D. W.; Hall, K. T.; Rudge, A. J. Anticoccidial activity of novel semisynthetic analogs of frenolicin B. Part I. Heterocycl. Commun. 1998, 4, 309-315.
13. Ellestad, G. A.; Whaley, H. A.; Patterson, E. L. Structure of frenolicin. J. Am. Chem. Soc. 1966, 88, 4109-4110.
14. Brimble, M. A.; Nairn, M. R.; Prabaharan, H. Synthetic strategies towards pyranonaphthoquinone antibiotics. Tetrahedron 2000, 56, 1937-1992.
15. Masquelin, T.; Hengartner, U.; Streith, J. Naphthopyranoquinone antibiotics. Novel enentioselective syntheses of frenolicin B and some of its stereoisomers. Helv. Chim. Acta 1997, 80, 43-58.
16. (a) Jacobsen, N.; Torssell, K. Alkylation of quinones with radicals: Generation of radicals in redox reactions. Justus Liebigs Ann. Chem. 1972, 763, 135-147.
17. (b) Jacobsen, N.; Torssell, K. Synthesis of naturally occurring quinones. Acta Chem. Scand. 1973, 27, 3211-3216.
18. Contant, P.; Haess, M.; Riegl, J.; Scalone, M.; Visnick, M. Synthesis of racemic frenolicin B and 5-epi-frenolicin B via intramolecular palladium-catalyzed aryloxycarbonylation. Synthesis 1999, 821-828.
19. (a) Ichihara, A.; Ubukata, M.; Oikawa, H.; Muramaki, K.; Sakamura, S. Total synthesis of (±) -nanaomycin A and (±) -frenolicin. Tetrahe-dron Lett. 1980, 21, 4469-4472.
20. (b) Masquelin, T.; Hengartner, U.; Streith, J. Coccidiostatic agents: Synthesis of some analogs of (±) -frenolicin B. Synthesis 1995, 780-786.
21. Mohan, H. R.; Rao, A. S. Enantioselective synthesis of (-) -5-deoxyjuglomycin A. Synth. Commun. 1993, 23, 2579-2585.
22. A detailed study of the stereochemical aspects of this transformation is reported in: Eid, C. N.; Shim, J.; Bikker, J.; Lin, M. Direct oxa-Pictet-Spengler cyclization to the natural (3a, 5) -trans stereochemistry in the synthesis of (+) -7-deoxyfrenolicin B and (+) -7-deoxykalafun-gin. J. Org. Chem. 2009, 74, 423-426.
23. (a) Tatsuta, K.; Akimoto, K.; Annaka, M.; Ohno, Y.; Kinoshita, M. Enantiodivergent total syntheses of nanaomycins and their enantiomers, kalafungins. Bull. Chem. Soc. Jpn. 1985, 58, 1699-1706.
24. (b) Tatsuta, K; Ozeki, H.; Yamaguchi, M.; Tanaka, M.; Okui, T.; Nakata, M. Total synthesis and biological evaluation of unnatural (-) -medermycin [(-) -lactoquinomycin]. J. Antibiot. 1991, 44, 901-902.
25. (a) Moore, H. W. Bioactivation as a model for drug design bioreductive alkylation. Science 1977, 197, 527-532.
26. (b) Moore, H. W.; Czerniak, R. Naturally occurring quinones as potential bioreductive alkylating agents. Med. Res. Rev. 1981, 1, 249-280.
27. Brimble, M. A.; Nairn, M. R. Reductive thioalkylation of a pyranonaphthoquinone. J. Chem. Soc., Perkin Trans. 1 2000, 317-322.
28. (a) Jha, S.; Karnani, N.; Lynn, A. M.; Prasada, R. Covalent modification of cysteine 193 impairs ATPase function of nucleotide-binding domain of a Candida drug efflux pump. Biochem. Biophys. Res. Commun. 2003, 310, 869-875.
29. (b) Nelson, N. C.; Taylor, S. S. Selective protection of sulfhydryl groups in cAMP-dependent protein kinase II. J. Biol. Chem. 1983, 258, 10981-10987.
30. Huang, X.; Begley, M.; Morgenstern, K. A.; Gu, Y.; Rose, P.; Zhao, H.; Zhu, X. Crystal structure of an inactive Akt2 kinase domain. Structure 2003, 11, 21-30.
31. Noort, D.; Hulst, A. G.; de Jong, L. P. A.; Benschop, H. P. Alkylation of human serum albumin by sulfur mustard in vitro and in vivo: mass spectrometric analysis of a cysteine adduct as a sensitive biomarker of exposure. Chem. Res. Toxicol. 1999, 12, 715-721.